Prelude Therapeutics secures Lilly deal. Citizens targets Prelude Therapeutics stock at USD 6.00

Published on 10/21/2026 at 01:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Phase 1 enrollment is scheduled for the fourth quarter of 2026. Citizens targets Prelude Therapeutics stock at USD 6.00 on October 14, 2026.

Clinical program milestones

Prelude announced a Lilly collaboration involving two breast cancer medicines on October 13, 2026.
Second-quarter 2026 revenue reached USD 5.70 million while net loss was USD 13.92 million.
Citizens assigned Prelude a USD 6.00 target on October 14, 2026.
Market capitalization stood at USD 204.3 million as of October 20, 2026.

PRLD, US74065P1012, Illustration mit AI erstellt.

Prelude Therapeutics (ISIN US74065P1012) secured a clinical trial collaboration and supply agreement with Eli Lilly on October 13, 2026. Citizens later assigned the stock a USD 6.00 price target, giving investors a second measurable reference for the clinical-stage biotechnology company.

Lilly adds two breast cancer drugs

According to GlobeNewswire, Lilly will supply abemaciclib and imlunestrant for Prelude's Phase 1 evaluation of PRT13722 in HR-positive, HER2-negative breast cancer. Prelude said the FDA had cleared the study under its Investigational New Drug application and that enrollment was on track to begin in the fourth quarter of 2026.

The collaboration does not provide a disclosed upfront payment. Its value is operational: Prelude gains access to two established treatment candidates while testing whether its KAT6A degrader can work in combination settings.

What does the deal change?

The financial backdrop remains important. Prelude generated USD 5.70 million of revenue and recorded a USD 13.92 million net loss in the second quarter of 2026, while cash stood at USD 155.2 million, according to Quartr. The company is therefore moving the pipeline toward clinical milestones while funding remains a central investor variable.

The chronology is clear: on October 13, 2026, Prelude announced the Lilly collaboration involving two supplied medicines; on October 16, 2026, it announced a two-person fireside chat at the Chardan Healthcare Conference; and on October 20, 2026, executives were scheduled to present at 2:00 p.m. ET, according to GlobeNewswire.

Analyst target and next date

Citizens reiterated a Market Outperform rating and set a USD 6.00 target on October 14, 2026, as reported by Investing.com. H.C. Wainwright separately maintained a Buy rating and USD 8.00 target in a note dated October 13, 2026, according to MarketBeat. Yahoo Finance lists November 11, 2026 as the estimated earnings date.

Stock value and clinical timing

Prelude's market capitalization stood at USD 204.3 million as of October 20, 2026, with a 52-week range of USD 1.17 to USD 6.83. The last available Nasdaq quotation was USD 3.53 on October 20, 2026 at 4:00 p.m. ET. The Lilly collaboration and fourth-quarter enrollment plan now give the valuation a defined clinical timetable.